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Abstract: Rheumatic disease is not a single disorder, but a group of more than 100 diseases 
that affect joints, connective tissues, and/or internal organs. Although rheumatic diseases like 
rheumatoid arthritis (RA), psoriatic arthritis, and ankylosing spondylitis (AS) differ in their 
pathogenesis and clinical presentation, the treatment of these inflammatory disorders overlaps. 
Non-steroid anti-inflammatory drugs are used to reduce pain and inflammation. Additional 
disease-modifying anti-rheumatic drugs are prescribed to slowdown disease progression, 
and is in RA more frequently and effectively applied than in AS. Biologicals are a relatively 
new class of treatments that specifically target cytokines or cells of the immune system, 
like tumor necrosis factor alpha inhibitors or B-cell blockers. A new kid on the block is the 
interleukin-17 (IL-17) inhibitor secukinumab, which has been recently approved by the US 
Food and Drug Administration for moderate-to-severe plaque psoriasis, psoriatic arthritis, 
and AS. IL-17 is a proinflammatory cytokine that has an important role in host defense, but 
its proinflammatory and destructive effects have also been linked to pathogenic processes 
in autoimmune diseases like RA and psoriasis. Animal models have greatly contributed to 
further insights in the potential of IL-17 blockade in autoimmune and autoinflammatory 
diseases, and have resulted in the development of various potential drugs targeting the IL-17 
pathway. Secukinumab (AIN457) is a fully human monoclonal antibody that selectively 
binds to IL-17A and recently entered the market under the brand name Cosentyx®. By bind-
ing to IL-17A, secukinumab prevents it from binding to its receptor and inhibits its ability to 
trigger inflammatory responses that play a role in the development of various autoimmune 
diseases. With secukinumab being the first in class to receive Food and Drug Administration 
approval, this article will further focus on this new biologic agent and review the milestones 
in its development and marketing.
Keywords: interlleukin-17, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis
Introduction
Rheumatic diseases are characterized by pain and loss of function in one or more areas 
of the musculoskeletal system. It is not a single disorder, but a group of more than 
100 diseases that affect joints; bones; cartilage; and connective tissues like tendons, 
ligaments, and muscles; they may also affect internal organs.
Arthritis (from Greek: arthro = joint, itis = inflammation) is one of the clinical 
manifestations of rheumatic diseases, and is characterized by pain, swelling, and 
stiffness of the affected synovial joints. Rheumatoid arthritis (RA) is the most common 
inflammation-driven rheumatic disease, which mainly affects the joints in a symmetrical 
manner and finally results in the destruction of cartilage and bone. This chronic auto-
immune disease has been associated with genetic predisposition (eg, HLA-DR4, cyto-
toxic T-lymphocyte-associated antigen [CTLA]-4, and PTPN22) and environmental 
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risk factors (eg, smoking and microorganisms), and is 
often accompanied by rheumatoid factor and anti-cyclic 
citrullinated protein antibodies as diagnostic and prognostic 
biomarkers for RA.1–3
In contrast to RA, psoriatic arthritis (PsA) and ankylosing 
spondylitis (AS) are considered seronegative rheumatic 
diseases; both PsA and AS are associated with genetic 
inheritance of the HLA-B27 gene.4,5 PsA is, like RA, also an 
inflammatory rheumatic disease characterized by arthritis and 
affects up to 30% of patients with the chronic skin condi-
tion psoriasis.6 Its peripheral joint involvement may range 
from mild asymmetric joint inflammation to severe erosive 
arthritis. AS, formerly also known as Bechterew’s disease, 
is a rheumatic disease of the axial skeleton that mainly 
affects the spine and the sacroiliac joint in the pelvis. This 
spondyloarthropathy is characterized by erosion, sclerosis, 
and ossification, which may result in complete fusion and 
rigidity of the spine.7
Despite the differences in pathogenesis and clinical 
presentation of RA, PsA, and AS, the treatment of these 
inflammatory rheumatic disorders is very overlapping. 
Nonsteroidal anti-inflammatory drugs are used to reduce 
pain and inflammation in rheumatic diseases; also, additional 
disease-modifying antirheumatic drugs, such as methotrex-
ate (MTX) and sulfasalazine, are prescribed to slow down 
disease progression, and are more frequently and effectively 
applied in RA than in AS.8 Biologicals form a relatively new 
class of treatments that specifically target specific cytokines 
or cells in the immune system. The most frequently applied 
biological agents approved for RA, PsA, and AS are tumor 
necrosis factor alpha (TNFα) inhibitors (including inflix-
imab, etanercept, adalimumab, golimumab, and certolizumab 
pegol).9,10 For RA, alternative and approved biologicals are 
directed against CTLA-4-driven T-cells (abatacept), CD20-
expressing B-cells (rituximab), or the IL-6 receptor tocili-
zumab, and many new drugs are still in the pipeline.11–14
However, alternatives for anti-TNF treatment failed to 
show efficacy in AS15,16 or are still in clinical trial for AS and 
PsA.17–19 PsA patients may also experience relief of symptoms 
by using the IL-12/IL-23 inhibitor ustekinumab, or by treat-
ment with the synthetic disease-modifying antirheumatic 
drug phosphodiesterase-4 inhibitor apremilast, which is also 
being tested in other rheumatic diseases like AS.20–22
A new kid on the block is the interleukin-17 (IL-17) 
inhibitor secukinumab, which has been recently approved by 
the US Food and Drug Administration (FDA) for moderate-
to-severe plaque psoriasis, PsA, and AS23,24 (Figure 1). 
Secukinumab (AIN457) is a fully human monoclonal 
antibody that selectively binds to IL-17A and is now reg-
istered by Novartis International AG under the brand name 
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Figure 1 Milestones in the development of the therapeutic anti-iL-17 antibody secukinumab.
Abbreviations: iL-17, interleukin 17; FDA, Food and Drug Administration; RA, rheumatoid arthritis; PsA, psoriatic arthritis; AS, ankylosing spondylitis; CTLA,  cytotoxic 
T-lymphocyte-associated antigen; FIXTURE, Full Year Investigative Examination of Secukinumab vs Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis; 
ERASURE, Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis.
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Cosentyx®. By binding to IL-17A, secukinumab prevents it 
from binding to its receptor and inhibits its ability to trigger 
inflammatory responses that play a role in the development 
of various autoimmune diseases.
IL-17 and its biological function
IL-17A is a proinflammatory cytokine that is a part of a family 
of six members (IL-17A to IL-17F).25 IL-17A, often referred 
to as IL-17, is a 17 kDa protein that is secreted as a dimer 
and was first described as CTLA-8 in the early nineties.26 
IL-17 is mainly produced by a specific T-helper subset, the 
Th17 cell,27,28 although other immune cells like γδT-cells, 
natural killer cells, natural killer T-cells, innate lymphoid 
cells, neutrophils, and mast cells have also been described to 
express or produce this cytokine.29–31 Upon binding of IL-17 
to its ubiquitously expressed receptor, IL-17RA pairs with 
IL-17RC to induce proinflammatory responses via TRAF6, 
ACT1, NF-κB, C/EBP, and MAPKs.32,33
The existence of IL-17-producing CD4+ T-cells, Th17 
cells, was only recently described after the discovery that 
the p40 subunit of IL-12 not only forms a heterodimer with 
IL-12p35, promoting interferon gamma-producing Th1 
cells, but is also shared with IL-23p19.34,35 IL-23, together 
with tumor growth factor beta and IL-6, contributes to Th17 
differentiation and survival under the control of transcrip-
tion factor RORγT.36,37 Th17 cells are abundant at mucosal 
interfaces like the gut, where IL-17 plays an important func-
tion in the protection against extracellular bacterial and fungal 
infections by upregulation of cytokines and antimicrobial 
peptides and by recruitment of neutrophils.38,39 In experi-
mental studies, IL-17 was demonstrated to be required for 
host defense against Klebsiella pneumoniae infection in 
the lungs and Citrobacter rodentium infection in the gut.40 
In patients suffering from the hyperimmunoglobulinemia E 
syndrome, an impaired IL-17 production by T-cells due to 
mutations in the Stat3 gene has been identified as the main 
cause of a devastating susceptibility for common pathogens 
like Staphylococcus aureus and Candida albicans, result-
ing in recurrent and often severe pulmonary infections, 
mucocutaneous candidiasis, eczema, and staphylococcal 
abscesses.41,42 These findings and the recently described 
effects of modulating the microbiome on T-cell biology 
underscore the importance of Th17 responses in mucosal 
homeostasis and immunity.43,44
Target identification: IL-17 in 
rheumatic diseases
Besides its role in immunity against infections, IL-17’s 
proinflammatory and destructive effects have also been 
linked to pathogenic processes in autoimmune diseases like 
RA, psoriasis, and PsA.45 Stimulation of synovial fibroblasts 
with IL-17 induces the expression of IL-6, IL-8, and matrix 
metalloproteinases,46 thereby promoting inflammation and 
cartilage destruction. In addition, IL-17 in synovial fluids 
from RA patients has been shown to induce the expression 
of RANKL,47 an essential mediator for osteoclastogenesis 
and bone resorption. Interesting, IL-17 has been described to 
synergize with various proinflammatory cytokines, including 
TNFα,48–51 implicating an important inflammatory and cata-
bolic function for IL-17 in disease pathogenesis (Figure 2).
In RA patients, increased systemic and local levels of 
this proinflammatory cytokine can be found. RA synovial 
tissue was found to spontaneously produce IL-17,52 and 
elevated levels of this cytokine have been reported in the 
synovial fluid of RA patients.49 Also in blood, increased 
IL-17 expression has been observed in patients with RA; 
besides increased cytokine levels in serum,53,54 more IL-17+ 
CD4+ Th17 cells were found in blood from RA patients 
compared to healthy controls.55 Recent studies reported 
that IL-17/Th17 levels were surprisingly increased by anti-
TNF treatment.56–58 Interestingly, in addition to CD4+ Th17 
cells, CD8+ IL-17+ cytotoxic T-cells have been described in 
the synovial fluid of PsA patients, and this Tc17 cell was 
shown to positively correlate with various markers of disease 
severity.59 In addition to the expression of IL-17, IL-17RC 
was also found to be upregulated in the synovial lining in 
PsA patients compared to osteoarthritis patients.60 For both 
PsA and AS, genome-wide association studies have identified 
polymorphisms of genes in the IL-17 pathway. PsA also has 
been associated with a polymorphism in the gene encoding 
for ACT1, a downstream signaling pathway of the IL-17 
receptor.61 A single-nucleotide substitution in the IL-23R 
gene has been demonstrated to be protective against AS.62 
Overall, IL-17 has been identified as a potential, interesting 
therapeutic target in RA, PsA, and AS, with further preclinical 
and clinical studies testing this hypothesis.
Preclinical development of anti-
IL-17 treatment
Animal models have greatly contributed to further insights 
in the potential of IL-17 blockade in autoimmune and auto-
inflammatory diseases. Although animal models for PsA 
and AS are limited, many IL-17 inhibition studies have been 
performed in joint inflammation models resembling RA.
The complete absence of IL-17 in mice during collagen-
induced arthritis development markedly suppressed disease 
onset as well as arthritis severity,63 and the effect of IL-17 
deficiency was even more pronounced in the spontaneous 
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arthritis development in mice deficient of the IL-1 receptor 
antagonist, where disease was completely prevented.64 
Another approach, knocking out the IL-17RA subunit fol-
lowed by chronic reactivated streptococcal cell wall-induced 
arthritis, demonstrated the requirement of IL-17R signaling 
for sustained and destructive joint inflammation.65
In contrast to complete absence of IL-17 signaling in 
transgenic mice, more refined inhibition of the IL-17 pathway 
in in vivo models has been applied using neutralizing anti-
bodies directed against this cytokine, or with soluble IL-17 
receptors fused to an immunoglobulin fragment crystalliz-
able (Fc)-domain to increase its circulation time. Blocking 
of endogenous IL-17 in the autoimmune collagen-induced 
arthritis model significantly reduced arthritis progression 
without affecting antigen-specific T- and B-cell responses,66 
and was even effective in established disease in IL-1RA-
deficient mice.67 In reactivation of the murine antigen-induced 
arthritis model with local exposure to a small amount of 
methylated bovine serum albumin as antigen, flare of the joint 
inflammation and subsequent enhanced destruction could be 
completely prevented using anti-IL-17 treatment.68 Interest-
ingly, the additive or synergistic effects of IL-17 with other 
cytokines were proven in murine collagen-induced arthritis, 
where blocking of IL-17 in combination with TNF or granu-
locyte macrophage colony stimulating factor more effectively 
reduced joint pathology than either treatment alone.69–71
Although collagen-induced arthritis is considered one 
of the classical models for RA, the SKG mouse model may 
also present with features of spondyloarthritides, including 
AS and PsA. Upon systemic injection with beta-glucan, 
autoimmune-prone SKG mice with mutated ZAP-70 develop 
peripheral and axial arthritis, ileitis, and psoriasis-like 
skin inflammation.72 Reduced arthritis, spondylitis, and 
enthesitis in the absence of IL-17 or after treatment with 
IL-23 inhibitors73 also support the concept of IL-17 as a 
therapeutic target in these rheumatic diseases. This has 
finally led to the development of various IL-17 inhibitors: 
secukinumab and ixekizumab targeting IL-17 cytokines and 
brodalumab targeting IL-17RA. With secukinumab being the 
first in class to receive FDA approval, this article will further 
focus on this new biologic agent and review the milestones 
in its development and marketing (Figure 1).
Safety profile of secukinumab
The safety profile of secukinumab in various Phase II/III clini-
cal trials on patients with rheumatic diseases was consistent 
with that observed with other biological therapies like etaner-
cept.74 Most observed adverse events were mild to moderate 
in severity. Infections were more frequent with secukinumab 
than with placebo; nasopharyngitis or infections of the upper 
respiratory tract were most often reported.75–79 Some cases of 
mild-to-moderate candidiasis were reported, which resolved 
spontaneously or with oral therapy.77 Grade 2–3 neutropenia 
was reported in a couple of patients, although this was not 
associated with increased risk of infection.80 The occurrence 
of reported serious adverse events could not be directly 
%RQH
+HDOWK\MRLQW $UWKULWLFMRLQW
$UWLFXODUFDUWLODJH
6\QRYLDOOLQLQJ
6\QRYLDOLQIODPPDWLRQ
%RQHHURVLRQDQGSDQQXVIRUPDWLRQ
&DUWLODJHGHVWUXFWLRQ
1HXWURSKLO0DFURSKDJH
6\QRYLRF\WH
2VWHRFODVW&KRQGURF\WH
2VWHREODVW,/6\QRYLDOIOXLG
Figure 2 Simplified scheme of IL-17 and its effector cells in the inflamed arthritic joint.
Notes: In the inflamed arthritic joint, IL-17 activates resident cells like synovial fibroblasts and chondrocytes, and recruits proinflammatory immune cells thereby contributing 
to joint inflammation, cartilage destruction, and bone erosion.
Abbreviation: iL-17, interleukin 17.
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linked to secukinumab treatment, and no deaths occurred.74–80 
Overall, after several Phase II and III clinical trials in psoriasis 
and various rheumatic diseases with no unexpected safety 
signals and no specific organ-related toxicities, secukinumab 
is in general considered safe and well tolerated.
One important safety issue, however, should be mentioned 
here that is not directly associated with secukinumab but with 
the IL-17R-inhibitor brodalumab, which showed significant 
clinical improvements in patients with moderate-to-severe pso-
riasis in the AMAGINE-2 and AMAGINE-3 trials.81 Mid 2015, 
Amgen Inc. unexpectedly announced that it was discontinu-
ing its co-development of brodalumab with AstraZeneca plc 
based on events of suicidal ideation and behavior in the 
brodalumab program.82 AstraZeneca plc claimed the obser-
vations of suicidal ideation and behavior are unlikely to be 
causally related to brodalumab therapy and is continuing full 
analysis of the AMAGINE studies. Without the exact details 
of these deaths in relation to their treatment, speculation on 
other confounding factors like a national surge in suicidality 
during the recent economic crisis,83 particularly affecting the 
study population in these trials, will not save the bad reputation 
of this IL-17R inhibitor. Despite all these, in January 2016, 
a Biologics License Application was submitted to the FDA by 
AstraZeneca plc in partnership with Valeant Pharmaceuticals, 
and a response is due by the end of the year.
Although secukinumab is far ahead of brodalumab in 
its clinical marketing and development, and suicidality is 
not a reported issue during its clinical trials, the concerns 
raised by the brodalumab program may influence ongoing 
secukinumab programs and may put mental health of future 
secukinumab users under the microscope.
Therapeutic value of secukinumab 
in psoriasis
Before discussing the therapeutic value of secukinumab in 
rheumatic diseases, the impressive results of this anti-IL-17 
antibody in the treatment of plaque psoriasis need to be men-
tioned here. Plaque psoriasis is a chronic inflammatory skin 
disease characterized by raised areas of inflamed skin covered 
with silvery-white scaly skin. After the first-in-man study 
with secukinumab already demonstrating highly significant 
effects on psoriasis severity,84 a Phase II, randomized, double-
blind, placebo-controlled trial was performed on 125 patients 
with moderate-to-severe plaque psoriasis.85 Subcutaneous 
injections with secukinumab at 4-week intervals resulted in 
significantly higher PASI75 scores, indicating at least 75% 
improvement from baseline in the Psoriasis Area and Severity 
Index score: 82% in the 150 mg arm (P,0.001) and 57% 
in the 75 mg arm (P=0.002) versus 9% in the placebo group 
(Papp, BRD2013).85 This study was followed by several 
Phase III trials, which further confirmed and proved the 
clinical efficacy of this anti-IL-17 antibody in psoriasis. The 
ERASURE, FIXTURE, and FEATURE trials achieved their 
primary efficacy endpoint of PASI75 at week 12 with over 
75% of the patients on 300 mg reaching PASI75 compared 
to ,5% in the placebo controls (3REF),74,86 resulting in 
rapid FDA approval for secukinumab for its first indication: 
moderate-to-severe plaque psoriasis23 (Figure 1). Key trials 
with secukinumab in psoriasis and rheumatic diseases are 
summarized in Table 1, providing a quick overview of the 
study design and primary endpoints in various Phase II/III 
clinical trials.
Therapeutic value of secukinumab 
in RA
Phase i
In 2010, the combined results of three clinical trials on 
the safety and possible efficacy of secukinumab in RA, 
psoriasis, and chronic noninfectious uveitis were published.84 
In the RA trial, 52 patients were enrolled (26 AIN457- and 
26 placebo-treated patients) for a 16-week study with two 
infusions of AIN457 (10 mg/kg) at an interval of 3 weeks. 
Although the primary efficacy endpoint was not achieved, this 
study provided the first indications of clinical responses to 
secukinumab. The American College of Rheumatology 20% 
response (ACR20) rate expressed as area under the response-
time curve was significantly higher in the secukinumab group 
than in the placebo control group, and this was also found for 
the 28-joint disease activity score (DAS28) and the serological 
inflammation marker C-reactive protein (CRP).84
Phase ii
In contrast to the impressive effects of anti-IL-17 treatment 
in psoriasis, published Phase II/III randomized controlled 
trials failed to demonstrate convincing data that secukinumab 
is effective in RA. The efficacy and safety of secukinumab 
were investigated in a double-blind, randomized, placebo-
controlled Phase II study including 237 RA patients with 
inadequate response to MTX, who were randomly assigned 
to monthly subcutaneous injections of 25, 75, 150, or 
300 mg secukinumab or placebo.75 At week 16, this resulted 
in ACR20 responses of 34.0%, 46.9%, 46.5%, and 53.7%, 
respectively, for the doses of secukinumab, compared to 
36.0% in the placebo arm. However, these differences did 
not reach statistical significance, thereby failing to show clini-
cal efficacy for secukinumab in RA. Although this primary 
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efficacy endpoint of significant ACR20 responses at 16 weeks 
was not achieved, beneficial effects of the secukinumab doses 
75, 150, and 300 mg were observed on DAS28–CRP scores.75 
When evaluating the long-term safety and efficacy in a 
follow-up study till 52 weeks, RA patients responding to 
secukinumab in the first 16 weeks showed a sustained clini-
cal response, or even further improvement in their response 
rates up to week 52.87 A recent Phase II biomarker study 
investigating the association of HLA-DRB1 alleles with 
clinical response to secukinumab was actually the first and 
only study to demonstrate the clinical efficacy of secuki-
numab over a placebo arm in RA with significantly better 
ACR20 response rates (87.1% in the secukinumab group vs 
25.0% in the placebo group) and reduced DAS28–CRP at 
week 12,80 although no association was found between the 
HLA-DRB1*04 allele and response to secukinumab treat-
ment. Current data from a limited set of Phase II trials are not 
convincing, and evidence for the efficacy of secukinumab in 
RA from a proper Phase III trial is still lacking. Preclinical 
research using the human RA synovium SCID mouse model 
demonstrated that anti-IL-17 was only effective when the 
synovial tissue was rich in CD3+ T-cells,88 suggesting that 
determining the T-cell dominance in RA patients using a 
set of biomarkers might help to predict the responsiveness 
to secukinumab treatment.
Phase iii
Various Phase III studies on secukinumab in RA have recently 
been completed (eg, NCT01350804 and NCT01640938) or 
are still in progress (NCT01901900 and NCT01770379).89,90 
More information will be obtained in the next few years 
on the clinical efficacy of this anti-IL-17 inhibitor in RA 
patients on MTX or with an inadequate response to anti-TNF 
agents. These results will yield a final verdict on the efficacy 
of secukinumab in RA and will further define the potential 
clinical utility of this treatment in patients with RA.
Application of secukinumab in PsA
Compared to RA, clinical trials on secukinumab for 
the treatment of PsA are much further in progress, and 
Novartis International AG filed a regulatory application for 
secukinumab as a PsA drug in the US and EU in Q2 2015. 
A Phase II proof-of-concept trial in 42 patients with active 
PsA did not meet its primary endpoint of ACR20 response 
at week 6, with ACR20 response in 39% of patients for 
secukinumab versus 23% for placebo (P=0.27), although 
significant improvement in the acute-phase proteins CRP 
and erythrocyte sedimentation rate (ESR) and quality of 
life as secondary endpoints suggested some clinical benefit 
from secukinumab treatment in PsA.91 Recent results from 
the randomized, placebo-controlled Phase III FUTURE 1 
and 2 trials (NCT01392326 and NCT01752634) indicate 
that secukinumab is indeed an efficacious treatment for 
patients with PsA.76,77 FUTURE 1 included 606 PsA patients 
randomly assigned to intravenous secukinumab followed 
by subcutaneous treatment with this IL-17 blocker at two 
different doses (150 or 300 mg), or placebo, and resulted 
in impressive and significant improvement in ACR20 and 
the American College of Rheumatology 50% response 
(ACR50), as well as two psoriasis area and severity indexes 
(PASI75 and PASI90) as secondary outcome parameters.76 
FUTURE 2 had a slightly different design with 397 PsA 
patients receiving subcutaneous injections of either placebo 
or secukinumab 75, 150, or 300 mg once a week for 4 weeks, 
continued every 4 weeks.77 Also in this Phase III trial, the 
primary efficacy endpoint was met for all the secukinumab 
doses, as secukinumab treatment clearly improved the signs 
and symptoms of PsA; with secukinumab 300 mg, 54% of 
the patients achieved ACR20 at week 24 versus 51% with 
150 mg, 29% with 75 mg, and 15% with placebo.77 In line 
with this impressive effect on the primary endpoint, for the 
doses 75 and 150 mg, significant effects were reported on 
various secondary endpoints, including PASI75 and PASI90, 
DAS28–CRP, and ACR50. Interestingly, clinical response 
rates were generally higher in anti-TNF-naive patients 
than in anti-TNF inadequate responders, with the low-dose 
(75 mg) secukinumab group failing to show significant 
ACR20 and ACR50 responses to secukinumab treatment 
upon stratification.77 Overall, these FUTURE trials have 
build an impressive record on the efficacy of secukinumab 
in PsA, resulting in the European and US FDA approval for 
secukinumab for PsA, together with the approval for AS, in 
November 2015 and January 2016, respectively.24,92
Treatment of AS
As already mentioned, the European Medicines Agency 
and FDA have approved secukinumab for the treatment 
of AS since multiple clinical trials have demonstrated its 
positive findings in AS. To test the safety and efficacy of 
secukinumab in AS, a randomized, double-blind, placebo-
controlled Phase II trial was performed among 30 patients 
with moderate-to-severe AS.93 Secukinumab administered 
intravenously 3 weeks apart was well tolerated and clini-
cally efficacious, as convincingly demonstrated by improved 
20% Assessment of SpondyloArthritis international Society 
response rates at week 6 (59.2% with secukinumab vs 24.5% 
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with placebo), with Bayesian analysis indicating a probability 
of 99.8% of secukinumab inducing greater response rates 
than placebo.93 A follow-up study demonstrated a sustained 
clinical response in the majority of these AS patients when 
secukinumab was continued at 3 mg/kg every 4 weeks until 
week 94, which was accompanied by regression of inflam-
matory spinal lesions as assessed by magnetic resonance 
imaging.94 Recent results of the Phase III MEASURE 1 and 
2 trials (NCT01358175 and NCT01649375) presented at 
the ACR conferences in Boston (2014)78 and San Francisco 
(2015)79,95 and published by Baeten et al96 confirmed that 
secukinumab resulted in rapid and significant improve-
ment of signs and symptoms in patients with active AS,78,79 
with ~61% of the patients in the 150 mg secukinumab arms 
showing 20% Assessment of SpondyloArthritis international 
Society response at week 16 compared to 28% in the placebo 
arms. Data from both the MEASURE trials also indicated 
that secukinumab was associated with a reduction of spinal 
inflammation as assessed by magnetic resonance imaging, 
as in ~80% of the patients treated with secukinumab for 
104 weeks no radiographic progression was observed.95 Other 
Phase III trials are ongoing to provide even more evidence 
on long-term safety and efficacy of secukinumab in AS 
(NTC02008916, NCT01863732, and NCT02159053), with 
results expected in 2017/2018.
Other rheumatic diseases: Behçet’s 
disease
A 24-week, randomized, double-blinded, placebo-controlled 
Phase III trial was conducted in 118 Behçet’s patients with 
posterior uveitis or panuveitis to assess the difference 
in the rate of recurrent exacerbations when treated with 
secukinumab versus placebo adjunctive to standard-of-care 
immunosuppressive therapy. This trial (NCT00995709) 
failed to demonstrate clinical improvement and showed 
a similar rate of recurrent ocular exacerbations during 
24 weeks of treatment. Additional trials investigating the 
efficacy of secukinumab in (Behçet’s) uveitis were halted 
(eg, NCT01093846, NCT01032915, NCT01090310, and 
NCT01103024) or withdrawn (NCT01327664).
Secukinumab in Crohn’s disease
Expectations were high when anti-IL-17 treatment was 
recently tested in Crohn’s disease (CD), but it results in dra-
matic failure of both secukinumab as well as AMG 827 for 
this indication.97,98 The multicenter Phase II trial on secuki-
numab in 59 patients with established moderate-to-severe 
CD was prematurely terminated. Secukinumab did not help 
in improving CD; moreover, worsening of the disease was 
reported as reflected in the high rate of serious adverse events 
as well as fungal infections.97 It seems that the role of IL-17 in 
diseases like CD has to be revisited, as more and more studies 
have uncovered the protective effects of IL-17 at mucosal 
sides, important for host defense and immune homeostasis 
together with other Th17 cytokines like IL-22.99
Secukinumab in autoinflammatory 
syndromes
In contrast to autoimmune diseases with a dysregulated 
adaptive immune system, autoinflammatory syndromes like 
familial Mediterranean fever and TNF receptor-associated 
periodic syndrome are caused by an exaggerated innate 
immune system response resulting in episodes of sponta-
neous inflammation affecting multiple organs. This major 
difference in pathogenesis also affects the type of treatments 
applied; rather than anti-TNF, CTLA-4-Ig, or B-cell-based 
biologicals, corticosteroids or anti-IL-1 treatment are most 
frequently applied. Many autoinflammatory diseases are 
linked to a dysfunctional caspase-1 activity and increased 
secretion of IL-1β by monocytes/macrophages, and the 
blocking of IL-1β has resulted in dramatic improvement in 
various autoinflammatory diseases.100 As the role of T-cells 
like Th17 cells in the pathogenesis of this type of inflam-
mations is minimal or absent, the potential of secukinumab 
treatment in autoinflammatory disease will be only based on 
IL-17 production by innate immune cells and is therefore 
expected to be very limited.
Conclusion: potential place in 
therapy
After demonstrating great clinical efficacy in psoriasis,74 
secukinumab received its first global approval in Japan on 
Boxing Day 2014 for the treatment of psoriasis and PsA. 
The secukinumab US regulatory application for moderate-to-
severe plaque psoriasis was filed in October 2013, with subse-
quent FDA recommendation in October 2014 and final FDA 
approval granted on January 21, 2015. Regulatory approval 
for secukinumab for the indications of AS and PsA was 
recently obtained in Europe and the US at the end of 2015/
in early 2016.24,92 Depending on the outcome of Phase III 
trials on secukinumab in RA, this may be followed by filing 
for RA in the coming years, although it must be stressed that 
convincing clinical efficacy data for secukinumab in RA are 
still lacking and most likely will not show similar efficacy 
as demonstrated in other rheumatic diseases such as PsA 
and AS. With secukinumab entering the market, international 
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treatment guidelines for various rheumatic diseases101–104 
may need to be updated, giving this IL-17 inhibitor as first 
in a novel class of drugs a position and ranking between the 
current available treatments for patients with various inflam-
matory rheumatic diseases.
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